JP2018506304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506304A5 JP2018506304A5 JP2017560478A JP2017560478A JP2018506304A5 JP 2018506304 A5 JP2018506304 A5 JP 2018506304A5 JP 2017560478 A JP2017560478 A JP 2017560478A JP 2017560478 A JP2017560478 A JP 2017560478A JP 2018506304 A5 JP2018506304 A5 JP 2018506304A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai
- vector
- guide region
- sequence
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009368 gene silencing by RNA Effects 0.000 claims 46
- 108091030071 RNAI Proteins 0.000 claims 45
- 239000013598 vector Substances 0.000 claims 35
- 239000002245 particle Substances 0.000 claims 33
- 150000007523 nucleic acids Chemical group 0.000 claims 25
- 241000702421 Dependoparvovirus Species 0.000 claims 18
- 241000124008 Mammalia Species 0.000 claims 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 13
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 241000700605 Viruses Species 0.000 claims 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 8
- 230000008488 polyadenylation Effects 0.000 claims 8
- 210000000234 capsid Anatomy 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 208000023105 Huntington disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000003612 virological effect Effects 0.000 claims 6
- 239000013608 rAAV vector Substances 0.000 claims 5
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 3
- 241000701022 Cytomegalovirus Species 0.000 claims 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 3
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 241000714474 Rous sarcoma virus Species 0.000 claims 3
- 108010006025 bovine growth hormone Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 241000649045 Adeno-associated virus 10 Species 0.000 claims 2
- 241000649046 Adeno-associated virus 11 Species 0.000 claims 2
- 241000649047 Adeno-associated virus 12 Species 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 2
- 241001115401 Marburgvirus Species 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 241000711798 Rabies lyssavirus Species 0.000 claims 2
- 241000710942 Ross River virus Species 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 210000004227 basal ganglia Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 210000003710 cerebral cortex Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 230000001697 htt accumulation Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 101710081722 Antitrypsin Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 108091033773 MiR-155 Proteins 0.000 claims 1
- 241000713869 Moloney murine leukemia virus Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 102000009190 Transthyretin Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001475 anti-trypsic effect Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 210000003161 choroid Anatomy 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 238000012226 gene silencing method Methods 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000005171 mammalian brain Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000013646 rAAV2 vector Substances 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078464A JP7526710B2 (ja) | 2015-02-10 | 2021-05-06 | バリアントＲＮＡｉ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114578P | 2015-02-10 | 2015-02-10 | |
| US62/114,578 | 2015-02-10 | ||
| PCT/US2016/017207 WO2016130589A2 (en) | 2015-02-10 | 2016-02-09 | VARIANT RNAi |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078464A Division JP7526710B2 (ja) | 2015-02-10 | 2021-05-06 | バリアントＲＮＡｉ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018506304A JP2018506304A (ja) | 2018-03-08 |
| JP2018506304A5 true JP2018506304A5 (enExample) | 2019-03-22 |
Family
ID=56614905
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560478A Pending JP2018506304A (ja) | 2015-02-10 | 2016-02-09 | バリアントＲＮＡｉ |
| JP2021078464A Active JP7526710B2 (ja) | 2015-02-10 | 2021-05-06 | バリアントＲＮＡｉ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078464A Active JP7526710B2 (ja) | 2015-02-10 | 2021-05-06 | バリアントＲＮＡｉ |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10450563B2 (enExample) |
| EP (1) | EP3256588A2 (enExample) |
| JP (2) | JP2018506304A (enExample) |
| KR (1) | KR102670852B1 (enExample) |
| CN (1) | CN107438671B (enExample) |
| AR (1) | AR103646A1 (enExample) |
| AU (3) | AU2016219396B2 (enExample) |
| CA (2) | CA3255657A1 (enExample) |
| CL (1) | CL2017002027A1 (enExample) |
| CO (1) | CO2017009083A2 (enExample) |
| CR (1) | CR20170406A (enExample) |
| EA (1) | EA201791805A1 (enExample) |
| EC (1) | ECSP17059343A (enExample) |
| HK (1) | HK1247641A1 (enExample) |
| IL (1) | IL253893B (enExample) |
| MA (1) | MA40819B1 (enExample) |
| MX (2) | MX2017010369A (enExample) |
| MY (2) | MY194175A (enExample) |
| PE (1) | PE20171382A1 (enExample) |
| PH (1) | PH12017501432A1 (enExample) |
| SG (3) | SG10201907396XA (enExample) |
| TN (1) | TN2017000354A1 (enExample) |
| TW (1) | TWI781079B (enExample) |
| UY (1) | UY36554A (enExample) |
| WO (1) | WO2016130589A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
| KR102584655B1 (ko) | 2014-11-14 | 2023-10-06 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| US10450563B2 (en) | 2015-02-10 | 2019-10-22 | Genzyme Corporation | Variant RNAi |
| WO2016161388A1 (en) | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| US20180228830A1 (en) * | 2015-10-23 | 2018-08-16 | Rena Therapeutics Inc. | Nucleic acid complex having at least one bulge structure |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| RU2758488C2 (ru) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
| AU2017268382B2 (en) | 2016-05-18 | 2023-09-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
| WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| CN110799647A (zh) | 2017-06-23 | 2020-02-14 | 马萨诸塞大学 | 双尾自递送sirna及相关的方法 |
| EP3684932A1 (en) * | 2017-09-22 | 2020-07-29 | Genzyme Corporation | Variant rnai |
| US20200377887A1 (en) * | 2017-09-22 | 2020-12-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| WO2019113266A1 (en) * | 2017-12-06 | 2019-06-13 | Ovid Therapeutics Inc. | Use of mir101 or mir128 in the treatment of seizure disorders |
| CN112368051A (zh) | 2018-03-23 | 2021-02-12 | 马萨诸塞大学 | 用于治疗骨病的基因治疗剂 |
| MX2020012077A (es) | 2018-05-15 | 2021-03-09 | Voyager Therapeutics Inc | Composiciones y metodos para el tratamiento de la enfermedad de parkinson. |
| WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| PH12021550254A1 (en) * | 2018-08-03 | 2023-02-06 | Genzyme Corp | Variant rnai against alpha-synuclein |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| EP3863662A1 (en) * | 2018-10-12 | 2021-08-18 | Genzyme Corporation | Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy |
| US20220098592A1 (en) * | 2019-01-09 | 2022-03-31 | Universidade De Coimbra | Double stranded rna and uses thereof |
| JP2022523467A (ja) | 2019-01-18 | 2022-04-25 | ユニバーシティ・オブ・マサチューセッツ | 動的な薬物動態を修飾するアンカー |
| US20220307024A1 (en) * | 2019-06-17 | 2022-09-29 | Alnylam Pharmaceuticals, Inc. | Delivery of oligonucleotides to the striatum |
| CN114502730A (zh) | 2019-08-09 | 2022-05-13 | 马萨诸塞大学 | 经化学修饰的靶向snp的寡核苷酸 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| EP4138860A4 (en) * | 2020-04-20 | 2024-08-07 | University Of Massachusetts | Oligonucleotides for msh3 modulation |
| WO2023093905A1 (zh) | 2021-11-29 | 2023-06-01 | 上海瑞宏迪医药有限公司 | Aadc、gdnf多核苷酸及其用于治疗帕金森病 |
| WO2023155918A1 (zh) | 2022-02-21 | 2023-08-24 | 上海瑞宏迪医药有限公司 | Vegf结合分子及其医药用途 |
| WO2024187106A2 (en) * | 2023-03-09 | 2024-09-12 | Leal Therapeutics, Inc. | Compositions and methods for modulating grin2a |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| CA2915124C (en) | 2001-11-13 | 2018-08-14 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| ATE513843T1 (de) * | 2002-09-25 | 2011-07-15 | Univ Massachusetts | Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna |
| AU2004239114B2 (en) * | 2003-05-14 | 2008-03-13 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
| US8283151B2 (en) | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
| US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
| EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
| WO2008134646A2 (en) | 2007-04-26 | 2008-11-06 | University Of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| PT2164967E (pt) * | 2007-05-31 | 2015-10-27 | Univ Iowa Res Found | Redução da toxicidade não dirigida do arn de interferência |
| EP2240783A2 (en) * | 2008-02-04 | 2010-10-20 | Galapagos N.V. | Molecular targets and compounds, methods to identify the same, useful in the treatment of neurodegenerative diseases. |
| AU2009214837A1 (en) | 2008-02-14 | 2009-08-20 | Michael Paul Marie Gantier | Immunostimulatory siRNA molecules |
| FR2929292A1 (fr) | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
| WO2011034811A1 (en) * | 2009-09-17 | 2011-03-24 | Sigma-Aldrich Co. | Short rna mimetics |
| EP3514232A1 (en) | 2010-04-23 | 2019-07-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| JP6224459B2 (ja) | 2011-02-17 | 2017-11-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法 |
| BR112014021104B1 (pt) | 2012-02-29 | 2023-03-28 | Sangamo Biosciences, Inc | Proteína de fusão de ocorrência não natural compreendendo um domínio de ligação de dna de dedo de zinco manipulado que se liga a um gene htt, seu uso, método in vitro de modificação da expressão de um gene htt em uma célula, e método de geração de um sistema modelo para o estudo da doença de huntington |
| US9550989B2 (en) * | 2013-10-03 | 2017-01-24 | Washington University | Rational design of microRNA-siRNA chimeras for multi-functional target suppression |
| ES2760263T3 (es) | 2014-03-21 | 2020-05-13 | Genzyme Corp | Tratamiento génico de la retinitis pigmentaria |
| EP4600255A3 (en) | 2014-05-02 | 2025-10-22 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
| ES2732023T3 (es) | 2014-12-24 | 2019-11-20 | Uniqure Ip Bv | Supresión del gen de la huntingtina inducida por ARNi |
| US10450563B2 (en) | 2015-02-10 | 2019-10-22 | Genzyme Corporation | Variant RNAi |
| EP3684932A1 (en) | 2017-09-22 | 2020-07-29 | Genzyme Corporation | Variant rnai |
-
2016
- 2016-02-09 US US15/549,895 patent/US10450563B2/en active Active
- 2016-02-09 WO PCT/US2016/017207 patent/WO2016130589A2/en not_active Ceased
- 2016-02-09 CN CN201680020699.5A patent/CN107438671B/zh active Active
- 2016-02-09 MY MYPI2020002819A patent/MY194175A/en unknown
- 2016-02-09 MA MA40819A patent/MA40819B1/fr unknown
- 2016-02-09 TN TNP/2017/000354A patent/TN2017000354A1/en unknown
- 2016-02-09 EA EA201791805A patent/EA201791805A1/ru unknown
- 2016-02-09 AU AU2016219396A patent/AU2016219396B2/en active Active
- 2016-02-09 SG SG10201907396XA patent/SG10201907396XA/en unknown
- 2016-02-09 MY MYPI2017702831A patent/MY181458A/en unknown
- 2016-02-09 KR KR1020177025286A patent/KR102670852B1/ko active Active
- 2016-02-09 CR CR20170406A patent/CR20170406A/es unknown
- 2016-02-09 CA CA3255657A patent/CA3255657A1/en active Pending
- 2016-02-09 SG SG11201706444TA patent/SG11201706444TA/en unknown
- 2016-02-09 MX MX2017010369A patent/MX2017010369A/es unknown
- 2016-02-09 PE PE2017001371A patent/PE20171382A1/es unknown
- 2016-02-09 CA CA2976075A patent/CA2976075A1/en active Pending
- 2016-02-09 HK HK18107116.4A patent/HK1247641A1/zh unknown
- 2016-02-09 EP EP16710035.3A patent/EP3256588A2/en active Pending
- 2016-02-09 JP JP2017560478A patent/JP2018506304A/ja active Pending
- 2016-02-10 SG SG10201912942YA patent/SG10201912942YA/en unknown
- 2016-02-10 UY UY0001036554A patent/UY36554A/es not_active Application Discontinuation
- 2016-02-10 AR ARP160100356A patent/AR103646A1/es unknown
- 2016-02-15 TW TW105104339A patent/TWI781079B/zh active
-
2017
- 2017-08-08 IL IL253893A patent/IL253893B/en unknown
- 2017-08-08 CL CL2017002027A patent/CL2017002027A1/es unknown
- 2017-08-09 PH PH12017501432A patent/PH12017501432A1/en unknown
- 2017-08-10 MX MX2022013005A patent/MX2022013005A/es unknown
- 2017-09-05 CO CONC2017/0009083A patent/CO2017009083A2/es unknown
- 2017-09-08 EC ECIEPI201759343A patent/ECSP17059343A/es unknown
-
2019
- 2019-09-10 US US16/566,565 patent/US10760079B2/en active Active
-
2020
- 2020-07-28 US US16/941,303 patent/US11781137B2/en active Active
-
2021
- 2021-05-06 JP JP2021078464A patent/JP7526710B2/ja active Active
-
2022
- 2022-06-17 AU AU2022204274A patent/AU2022204274B2/en active Active
-
2023
- 2023-10-09 US US18/483,474 patent/US20240182896A1/en active Pending
-
2025
- 2025-07-16 AU AU2025205501A patent/AU2025205501A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506304A5 (enExample) | ||
| JP2020019772A5 (enExample) | ||
| JP2020535803A5 (enExample) | ||
| RU2017116576A (ru) | Композиции и способы лечения бокового амиотрофического склероза (als) | |
| RU2018140499A (ru) | Способы и композиции для лечения хореи гентингтона | |
| JP2017510298A5 (enExample) | ||
| IL273394B1 (en) | Variant rnai | |
| JP2017535266A5 (enExample) | ||
| HRP20192141T1 (hr) | Genska terapija za retinitis pigmentosa | |
| JP2017509632A5 (enExample) | ||
| JP2020500541A5 (enExample) | ||
| JP6929230B2 (ja) | スペーサーを含む核酸分子およびその使用の方法 | |
| US12031148B2 (en) | RNA adeno-associated virus (RAAV) vector and uses thereof | |
| JP2025507958A (ja) | 操作された核内低分子ＲＮＡ（ｓｎＲＮＡ）を含む組成物および方法 | |
| JP2020519294A5 (enExample) | ||
| US20250163455A1 (en) | Intron fragments | |
| JPWO2021067448A5 (enExample) | ||
| WO2019156115A1 (ja) | オリゴデンドロサイト特異的プロモータ、ＰＬＰ１遺伝子に特異的なｍｉＲＮＡ、該プロモータ及び／又は該ｍｉＲＮＡを含むベクター並びに該ベクターを含む医薬組成物 | |
| JP2025536927A (ja) | ＲＮＡ編集のためのプログラム可能なｓｎＲＮＡを含む組成物及び方法 | |
| AU2022282057B2 (en) | Novel dual helper plasmid | |
| JPWO2020028816A5 (enExample) | ||
| CN118291541B (zh) | 一种诱导型启动子 | |
| NZ735289B2 (en) | VARIANT RNAi | |
| NZ735289A (en) | Variant rnai | |
| RU2021105232A (ru) | ВАРИАНТ СРЕДСТВА ДЛЯ RNAi ПРОТИВ АЛЬФА-СИНУКЛЕИНА |